Intervention Review

You have free access to this content

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

  1. Suetonia C Palmer1,
  2. Sankar D Navaneethan2,
  3. Jonathan C Craig3,4,
  4. David W Johnson5,
  5. Vlado Perkovic6,
  6. Jorgen Hegbrant7,
  7. Giovanni FM Strippoli3,4,8,9,10,11,*

Editorial Group: Cochrane Kidney and Transplant Group

Published Online: 31 MAY 2014

Assessed as up-to-date: 5 JUN 2012

DOI: 10.1002/14651858.CD007784.pub2


How to Cite

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GFM. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD007784. DOI: 10.1002/14651858.CD007784.pub2.

Author Information

  1. 1

    University of Otago Christchurch, Department of Medicine, Christchurch, New Zealand

  2. 2

    Glickman Urological and Kidney Institute, Cleveland Clinic, Department of Nephrology and Hypertension, Cleveland, OH, USA

  3. 3

    The University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia

  4. 4

    The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia

  5. 5

    Princess Alexandra Hospital, Department of Nephrology, Woolloongabba, Queensland, Australia

  6. 6

    The George Institute for Global Health, Renal and Metabolic Division, Camperdown, NSW, Australia

  7. 7

    Diaverum Renal Services Group, Medical Office, Lund, Sweden

  8. 8

    University of Bari, Department of Emergency and Organ Transplantation, Bari, Italy

  9. 9

    Mario Negri Sud Consortium, Department of Clinical Pharmacology and Epidemiology, Santa Maria Imbaro, Italy

  10. 10

    Diaverum, Medical-Scientific Office, Lund, Sweden

  11. 11

    Amedeo Avogadro University of Eastern Piedmont, Division of Nephrology and Transplantation, Department of Translational Medicine, Novara, Italy

*Giovanni FM Strippoli, Cochrane Renal Group, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, 2145, Australia. strippoli@negrisud.it. gfmstrippoli@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 31 MAY 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.

*Other - short duration, animal studies
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study
[Analysis 1.1]
Analysis 1.1. Comparison 1 Statins versus placebo or no treatment, Outcome 1 Major cardiovascular events.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Statins versus placebo or no treatment, Outcome 2 All-cause mortality.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Statins versus placebo or no treatment, Outcome 3 Cardiovascular mortality.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Statins versus placebo or no treatment, Outcome 4 Fatal and non-fatal myocardial infarction.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Statins versus placebo or no treatment, Outcome 5 Fatal and non-fatal stroke.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Statins versus placebo or no treatment, Outcome 6 End-stage kidney disease.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Statins versus placebo or no treatment, Outcome 7 Elevated creatine kinase (rhabdomyolysis).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Statins versus placebo or no treatment, Outcome 8 Elevated liver enzymes.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Statins versus placebo or no treatment, Outcome 9 Withdrawal due to adverse events.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Statins versus placebo or no treatment, Outcome 10 Cancer.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Statins versus placebo or no treatment, Outcome 11 End of treatment creatinine clearance (CrCl).
[Analysis 1.12]
Analysis 1.12. Comparison 1 Statins versus placebo or no treatment, Outcome 12 End of treatment proteinuria.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Statins versus placebo or no treatment, Outcome 13 Total cholesterol.
[Analysis 1.14]
Analysis 1.14. Comparison 1 Statins versus placebo or no treatment, Outcome 14 LDL cholesterol.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Statins versus placebo or no treatment, Outcome 15 HDL cholesterol.
[Analysis 1.16]
Analysis 1.16. Comparison 1 Statins versus placebo or no treatment, Outcome 16 Triglycerides.
[Analysis 1.17]
Analysis 1.17. Comparison 1 Statins versus placebo or no treatment, Outcome 17 Sensitivity analysis: major cardiovascular events.
[Analysis 1.18]
Analysis 1.18. Comparison 1 Statins versus placebo or no treatment, Outcome 18 Sensitivity analysis: all-cause mortality.
[Analysis 1.19]
Analysis 1.19. Comparison 1 Statins versus placebo or no treatment, Outcome 19 Sensitivity analysis: fatal and non-fatal myocardial infarction.
[Analysis 1.20]
Analysis 1.20. Comparison 1 Statins versus placebo or no treatment, Outcome 20 Sensitivity analysis: cardiovascular mortality.